Latest & greatest articles for pioglitazone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pioglitazone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pioglitazone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pioglitazone

81. Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents

Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents Boucher M, McAuley L, Brown A, Keely E, Skidmore B Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Boucher M, McAuley L, Brown A, Keely E, Skidmore B. Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2003: 17 Authors' objectives 1. To evaluate the evidence that compares rosiglitazone or pioglitazone with other oral anti-diabetic agents (including insulin), either when used

Health Technology Assessment (HTA) Database.2003

82. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.

Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. BACKGROUND: Pioglitazone is an oral hypoglycemic agent in the thiazolidinedione class. Only one case of hepatotoxicity related to this agent has previously been reported. OBJECTIVE: To report the clinical course of a patient with hepatitis after therapy with pioglitazone. DESIGN: Case report. SETTING: A community hospital. PATIENT: A 49-year-old diabetic man taking pioglitazone, 30 mg/d. INTERVENTION: Discontinuation (...) of pioglitazone therapy. MEASUREMENTS: Serum aminotransferase and bilirubin levels, standard blood tests for causes of hepatitis and cirrhosis other than drug toxicity, and liver biopsy. RESULTS: After 6 months of pioglitazone therapy, significant hepatic dysfunction developed. Blood tests excluded viral, metabolic, and autoimmune disorders. Liver biopsy showed mixed hepatocellular-cholestatic injury compatible with drug toxicity. After treatment with pioglitazone was discontinued, liver enzyme values

Annals of Internal Medicine2002

83. Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis

Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis Boucher M, McAuley L, Brown A, Keely E, Skidmore B Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boucher M, McAuley L, Brown A, Keely E, Skidmore B. Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 76 Authors' objectives The aims of this report are: 1. To evaluate the evidence

Health Technology Assessment (HTA) Database.2002

84. Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis

Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis Boucher M, McAuley L, Brown A, Keely E, Skidmore B Authors' objectives To evaluate the effectiveness (...) of rosiglitazone and pioglitazone compared with other oral antidiabetic agents in the treatment of type 2 diabetes. Searching MEDLINE, EMBASE, HealthSTAR, Pascal, SciSearch and TOXLINE (all from 1990 to 2001) and the Cochrane Library (Issue 3, 2002) were searched for studies published in English and other languages. Database updates and alerts were set up on Adis LMS Drug Alerts, Current Contents Search, EMBASE Alert, MEDLINE, Pascal, Pharmaceutical News Index and SciSearch. Additional searches were performed

DARE.2002

85. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review

The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review Chilcott J, Wight J, Lloyd Jones M, Tappenden P Authors' objectives To evaluate the incremental clinical and cost (...) -effectiveness of pioglitazone in its licenced indication (UK product licence), in combination with insulin, and as monotherapy (unlicensed indications). The licensed indication specifies the following: 'only in oral combination treatment of type 2 diabetes mellitus in patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea'; 'in combination with metformin only in obese patients'; 'in combination with a sulphonylurea only

DARE.2001

86. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review

The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review Chilcott J, Wight J, Lloyd Jones M, Tappenden P Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chilcott J, Wight J, Lloyd Jones M, Tappenden P. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review. Health Technology Assessment 2001; 5(19): 1-71 Authors' objectives This review was performed to evaluate the use of pioglitazone in its licensed indication, in combination with metformin

Health Technology Assessment (HTA) Database.2001

87. Guidance on the use of pioglitazone for type 2 diabetes mellitus

Guidance on the use of pioglitazone for type 2 diabetes mellitus Guidance on the use of pioglitazone for type 2 diabetes mellitus Guidance on the use of pioglitazone for type 2 diabetes mellitus National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use (...) of pioglitazone for type 2 diabetes mellitus. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 21. 2001 Authors' objectives To provide guidance on the use of pioglitazone for type 2 diabetes mellitus. Authors' conclusions Guidance 1.1 Pioglitazone is effective at reducing blood glucose when added to oral monotherapy of either metformin or sulphonylurea for patients who have inadequate control of blood glucose on these agents alone. 1.2 Patients with inadequate blood

Health Technology Assessment (HTA) Database.2001

88. The clinical effectiveness and cost-effectiveness of pioglitazone and type 2 diabetes mellitus

The clinical effectiveness and cost-effectiveness of pioglitazone and type 2 diabetes mellitus The clinical effectiveness and cost-effectiveness of pioglitazone in type 2 diabetes mellitus: a rapid and systematic review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation

NIHR HTA programme2001

89. Actos (Pioglitazone Hydrochloride)

Actos (Pioglitazone Hydrochloride) Drug Approval Package:Actos (Pioglitazone Hydrochloride) NDA# 021073 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Actos (Pioglitazone Hydrochloride) Tablets Company: Takeda Armerica Research & Dev. Ctr. Inc. Application No.: 021073 Approval Date: 7/15/1999 (PDF) (995 KB) Final Printed Labeling (PDF) ( MB) (PDF) ( MB) Medical Review(s) (PDF) (3 MB) (PDF) (2.4 MB) (PDF) (2.6 MB) (PDF) (448 KB) Pharmacology

FDA - Drug Approval Package1999